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Early-onset atrial fibrillation 
patients show reduced left 
ventricular ejection fraction and 
increased atrial fibrosis
Laura Andreasen1,2,6 ✉, Litten Bertelsen3,6, Jonas Ghouse1,2, Pia R. Lundegaard1,2, 
Gustav Ahlberg1,2, Lena Refsgaard1,2, Torsten B. Rasmussen4, Hans eiskjær4, Stig Haunsø1,5, 
niels Vejlstrup3, Jesper H. Svendsen3,5 & Morten S. olesen1,2
Atrial fibrillation (AF) has traditionally been considered an electrical heart disease. However, genetic 
studies have revealed that the structural architecture of the heart also play a significant role. We 
evaluated the functional and structural consequences of harboring a titin-truncating variant (TTNtv) 
in AF patients, using cardiac magnetic resonance (CMR). Seventeen early-onset AF cases carrying a 
TTNtv, were matched 1:1 with non-AF controls and a replication cohort of early-onset AF cases without 
TTNtv, and underwent CMR. Cardiac volumes and left atrial late gadolinium enhancement (LA LGE), as 
a fibrosis proxy, were measured by a blinded operator. Results: AF cases with TTNtv had significantly 
reduced left ventricular ejection fraction (LVEF) compared with controls (57 ± 4 vs 64 ± 5%, P < 0.001). 
We obtained similar findings in early-onset AF patients without TTNtv compared with controls (61 ± 4 
vs 64 ± 5%, P = 0.02). We furthermore found a statistically significant increase in LA LGE when 
comparing early-onset AF TTNtv cases with controls. Using state-of-the-art CMR, we found that early-
onset AF patients, irrespective of TTNtv carrier status, had reduced LVEF, indicating that early-onset AF 
might not be as benign as previously thought.
Atrial fibrillation (AF) is the most common cardiac arrhythmia. Patients with AF have an increased risk of cardi-
ovascular morbidity, such as stroke and heart failure, and a 1.5–2 fold increased risk of death1.
Genome-wide association studies (GWAS) have associated common variants in structural genes, such as 
SYNPO2L2 and TTN3 with AF. Also, rare loss-of-function variants in the TTN and MYL4 gene have recently been 
linked with early-onset AF4–7. With the growing body of evidence implicating structural genes with AF, an “atrial 
cardiomyopathy” as an underlying substrate for AF has been postulated8,9. Patients with an early onset of AF, low 
CHA2DS2VASc score and a normal echocardiographic examination are in general considered to have a relatively 
benign arrhythmia, and current guidelines do not advocate regular clinical assessment1. Given the fact that an 
early debut may indicate a strong heritable component, and that recent evidence suggests impairment in pathways 
associated with the structural architecture of the cardiomyocyte, it is imperative to explore the clinical course of 
disease in these early-onset patients10,11.
In this study, we aimed to describe the systolic and diastolic function of the left atrium (LA) and ventricle (LV) 
in patients with early-onset AF and titin-truncating variants (TTNtv). Furthermore, we quantified left atrial 
late gadolinium enhancement (LA LGE) as a proxy for the degree of fibrosis using cardiac magnetic resonance 
(CMR).
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Methods
Study participants. The current study is a clinical follow-up study on a large whole-exome sequencing study 
of early-onset AF, including familial and non-familial AF patients, and the design has previously been described 
in detail4.
In brief, all individuals with permanent residence in Denmark are assigned a unique civil registration num-
ber. Using the civil registration number, we identified all Danish families with three or more family members 
diagnosed with AF by cross linkage between The National Patient Register and The Danish Family Relations 
Database. The National Patient Register contains information on all in- and out-of-hospital patient activities 
in Denmark since 197812. The Danish Family Relations Database contains information on parent-child links in 
the Danish population and allows for construction of pedigrees11. In total, we identified 24 families with at least 
three members from the same family with an AF registry diagnosis, resulting in 77 familial AF cases available for 
whole-exome sequencing. A replication cohort of 399 unrelated early-onset non-familial AF patients were also 
recruited using the Danish National Registries and ICD-10 code I48.9. These were characterized by disease-onset 
before the age of 40 with normal echocardiographic examination and no traditional risk factors for AF at the 
time of diagnosis (hyperthyroidism, diabetes, mitral/aortic valve disease, ischemic heart disease, congestive heart 
failure, congenital heart malformation, or cardiomyopathy).
The familial AF cases had whole-exome sequencing performed and the cohort of early-onset AF patients 
underwent targeted deep sequencing of TTN4. Unrelated, early-onset AF patients (familial or non-familial) har-
boring a TTNtv were offered a CMR. These were matched 1:1 with a cohort of unrelated early-onset AF patients 
without TTNtv, confirmed by targeted deep sequencing. This was done to evaluate whether findings observed in 
the TTNtv cohort were generalizable to a non-TTNtv cohort of early-onset AF patients. Matching criteria were 
gender, age ± 5 years, and body mass index (BMI) ± 1. All early-onset AF patients who were offered CMR, both 
with and without TTNtv, had disease-onset before the age of 40 with normal echocardiographic examination and 
no traditional risk factors for AF at the time of diagnosis.
Control group. We invited a control group for participation through public advertising. Only individuals 
free of any overt cardiac disease by self-report were included. The control group was matched using the same 
matching criteria as listed above. Individuals were excluded from the study if they had any general CMR contrain-
dications, i.e. pacemaker, metal implants, claustrophobia, pregnancy, reduced kidney function (plasma-creatinine 
<60 μmol/l) and previous allergic reactions to the contrast medium gadobutrol.
All participating individuals were given written information and gave written informed consent. The study 
was approved by the scientific ethics committee for the Capital Region of Denmark (protocol number H-1-2011-
044) and complies with the Declaration of Helsinki.
Image acquisition. CMR scans were performed in a 1.5 Tesla scanner (Aera, Siemens Healthcare, Germany) 
using an 18-channel body coil. After scout sequences, long axis cine (two-, three- and four-chamber) images were 
acquired for planning stacks and aid in delineation of chambers. An axial cine stack covering atria and ventricles 
and a short axis cine stack covering the entire LV were obtained for measurement of LA and LV volumes, respec-
tively (steady-state free precession (SSFP) cine sequences [8 mm; 2 mm gap; 25 phases; field of view (320–360) × 
360 adjusted for each patient; matrix size (182–224) × (138–224)] at 10–15 second end-expiratory breath-holds).
LA LGE scans were performed 20 minutes after bolus injection of 0.2 mmol/kg gadobutrol (Gadovist, 
Bayer, Berlin, Germany), with a maximum of 15 mmol in total. The LA LGE scan consisted of a free-breathing 
respiration-navigator-gated 3D FLASH sequence with FatSat and ECG-gating (end-atrial diastole, determined 
from four chamber cine). Typical parameters were: TR/TE 4.67/1.94 ms, bandwidth 300 Hz, inversion time 
according to scout-sequence (270–310 ms), flip angle 20°, slice thickness 1.5 mm, pixel spacing 0.70 ×0.70 mm 
and no parallel-imaging.
Image analyses. CMR analyses were performed in CVI (v. 5.6.6, Circle Cardiovascular Imaging Inc., 
Calgary, Canada). The images were analyzed by a cardiologist with expertise in CMR who was blinded to par-
ticipant phenotype and genotype. On short axis cine images, LV endocardial borders were traced manually 
from end-systolic to end-diastolic phases. Left ventricular outflow tract (LVOT) was included in the blood pool; 
papillary muscles were excluded, using windowing for the endocardial border. Epicardium was delineated in 
end-diastolic and end-systolic phases to compare left myocardial mass in end-diastole and end-systole. Left ven-
tricular ejection fraction (LVEF) was defined as abnormal when below 58%13.
LA endocardial borders were traced manually from atrial end-diastolic to end-systolic phases. The pulmonary 
veins were excluded from the volume and appendages were included. From individual time-volume curves were 
read atrial volumes corresponding to maximum volume (LAmax), mid-diastolic volume (LAmdv), volume before 
atrial contraction (LAbac), and minimum volume (LAmin) (see Fig. 1). In participants with AF during CMR we 
only measured LAmax, hence no cyclic volumes nor emptying fractions were measured. All volumes were indexed 
to body surface area. From measured volumes were calculated the following:
LA active emptying volume: LA AEV = LAbac − LAmin
LA passive emptying volume: LA PEV = LAmax − LAmdv
LA conduit volume: LA CEV = LVSV – (LA PEV + LA AEV)
LA total emptying fraction: LA TEF = (LAmax − LAmin)/LAmax *100
LA passive emptying fraction: LA PEF = (LAmax − LAmdv)/LAmax *100
LA active emptying fraction: LA AEF = (LAbac − LAmin)/LAbac *100
LA passive/active ratio = (LA PEV/LA AEV) *100
3Scientific RepoRtS |        (2020) 10:10039  | https://doi.org/10.1038/s41598-020-66671-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
LA LGE scans were analyzed manually off-line. On all axial images, the blood pool as well as the atrial epi- 
and endocardium were segmented. Pulmonary veins and mitral valves were excluded for fibrosis analyses. All 
wall intensities above three standard deviations (SD) of the blood pool intensity on every slice were considered 
enhancement. The total volume and percentage of fibrosis were registered.
Statistical analyses. Baseline characteristics of the study participants were expressed as number (percent-
age), mean (SD) or median (interquartile range [IQR]) where appropriate. In the case of non-normality, contin-
uous variables were log transformed.
Student’s t-tests were used to test for differences in LA and LV parameters between the early-onset AF cases 
with TTNtv compared with the controls and between the early-onset AF replication cohort and the controls. 
Sensitivity analyses were performed with linear regression models to test the effect of adjustment with antihyper-
tensive medication (beta blockers, aldosterone antagonists, angiotensin-converting-enzyme inhibitors, furosem-
ide and angiotensin II receptor antagonists; yes/no) and heart rate.
We also used Student’s t-test to compare the levels of LA LGE between the study groups. To account for the 
effect of catheter ablation on cardiac fibrosis14, we conducted a subgroup analysis, where individuals were cate-
gorized by prior catheter ablation procedure (yes/no). Using this approach, we aimed to isolate the link between 
fibrosis and AF, without the preponderance of ablation-related fibrosis.
The assumptions of linearity, homoscedasticity and normality were tested graphically using plots of observed 
versus predicted values and plots of residuals versus predicted values or the observed exposure values. No viola-
tions were observed.
A two-sided p-value of less than 0.05 was considered significant. All analyses were conducted using R, version 3.5.3.
Results
Clinical characteristics. Baseline characteristics of the study participants are shown in Table 1.
The study participants were diagnosed with AF at a young age (median age of disease-onset 25 years, IQR 
22–29), and had on average been diagnosed with AF for two decades (mean time since AF diagnosis 18 years (± 
11 years) at the time of study. Follow-up clinical echocardiographic examinations (median AF duration 9 years, 
IQR 4–11), revealed normal LVEF and ventricular dimensions in all AF TTNtv patients except one. This patient 
had suffered from tachycardia-induced heart failure and LA dilation 27 years after diagnosis and now presented 
with normal LA dimensions and LVEF when subjected to CMR. At the time of study, none of the early-onset AF 
patients with or without TTNtv had been diagnosed with dilated cardiomyopathy (DCM).
The left ventricle. In total, 14 early-onset AF TTNtv cases and 17 controls had complete volumetric meas-
urements of LA and LV. Two patients were excluded due to AF during CMR, one patient was excluded due to 
inability to comply with breath-holding instructions.
Data from comparisons of volumetric measurements of LA and LV are summarized in Table 2 and 
time-volume curves from the LA and LV are presented in Fig. 1.
When examining the LV parameters, we found significantly reduced LVEF (57 ± 4 vs 64 ± 5%, P < 0.001), 
due to higher LV end-systolic volume (LVESV; 41 ± 7 vs 34 ± 8 ml/m2, P = 0.013) in early-onset AF TTNtv cases 
compared with controls. We found no statistically significant difference in LV end-diastolic volume (Table 2). To 
validate these findings, we investigated the same volumetric parameters in a replication cohort of early-onset AF 
patients without TTNtv. In total, 15 early-onset AF patients had complete volumetric measurements of LA and 
LV. Two patients were excluded due to AF during CMR. We found similar trends, albeit a smaller reduction in 
Figure 1. Time-volume-curves. Time-volume curves of the left atrium and left ventricle in early-onset AF 
cases with TTNtv, early-onset AF without TTNtv and controls. All volumes are indexed to BSA. Shown as mean 
with error bars representing standard error of the mean. AF, atrial fibrillation; BSA, body surface area; LA, left 
atrium; LAbac, volume before atrial contraction; LAmax, maximum volume; LAmdv, mid-diastolic volume; 
LAmin, minimum volume; LV, left ventricle; TTNtv, titin-truncating variants.
4Scientific RepoRtS |        (2020) 10:10039  | https://doi.org/10.1038/s41598-020-66671-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
LVEF (61 ± 4 vs 64 ± 5%, P = 0.020) and increase in LVESV (39 ± 5 vs 34 ± 8 ml/m2, P = 0.033) in early-onset AF 
patients without TTNtv compared with controls. The results did not materially change when adjusting for anti-
hypertensive medication or heart rate. However, LVESV was no longer statistically significant when comparing 
early-onset AF patients without TTNtv with controls and adjusting for antihypertensive medication.
The left atrium. When examining the LA volumetric measurements, the mid-cyclic volume LAbac was 
significantly reduced in early-onset AF patients with TTNtv compared with controls (35 ± 9 vs 44 ± 11 ml/m2, 
P = 0.025). The lower mid-cyclic volume could also be seen in a reduced LA active emptying volume (11 ± 4 vs 
16 ± 4 ml/m2, P = 0.002), whereas we found no significant difference in LA passive emptying volumes between 
groups. The reduction in the actively emptied volume could also be seen in a significantly higher LA passive/
active ratio in early-onset AF TTNtv cases compared with controls (168 ± 2 vs 115 ± 2, P = 0.032) (Table 2). 
We found no significant differences in LA volume indices between early-onset AF patients without TTNtv and 
controls. When adjusting for antihypertensive medication, the other mid-cyclic volume LAmdv also became signif-
icantly different between early-onset AF TTNtv cases and controls (mean difference −7 ml/m2, 95% confidence 
interval −14; −1, P = 0.032). Adjustment for antihypertensive medication did not alter the remaining compar-
isons. When adjusting for heart rate, LAbac was no longer significantly different between early-onset AF TTNtv 
cases and controls.
LA LGE measurements. A total of 17 early-onset AF TTNtv cases and 13 controls had complete LA LGE 
CMR scans performed. Four controls were excluded due to low quality of the LA LGE scan.
We found a significant increase in the level of LA LGE (8 ± 2 vs 3 ± 3%, P < 0.001) when comparing 
early-onset AF TTNtv cases with controls. This finding could not be replicated in early-onset AF patients without 
TTNtv compared with controls.
To investigate whether the difference in LA LGE levels was solely caused by previous ablation therapy proce-
dures, we furthermore compared all non-ablated and ablated early-onset AF patients with controls. We found a 
significant increase in LA LGE in non-ablated early-onset AF patients compared with controls (4 ± 2 vs 3 ± 3%, 
P = 0.042), and, as anticipated, in ablated early-onset AF patients compared with controls (14 ± 2 vs 3 ± 3%, 
P < 0.001) (Fig. 2).
AF with 
TTNtv 
(n = 17)
AF without 
TTNtv 
(n = 17)
Controls 
(n = 17) P-value† P-value‡
Gender, male, n (%) 14 (82) 14 (82) 14 (82) 1.0 1.0
Age of AF onset, years 
(median [IQR]) 25 (22–29) 25 (22–29) — —
Age at study time (median 
[IQR]) 42 (39–45) 42 (40–45) 42 (37–44) 0.9 0.9
Height, cm (mean [SD] 183 (8) 185 (9) 180 (8) 0.3 0.4
BMI, kg/m2 (mean [SD]) 26 (4) 27 (4) 26 (3) 0.8 0.6
Smoking, current or 
previously, n (%) 6 (35) 7 (41) 5 (29) 0.7 0.5
Alcohol consumption per 
week (mean [SD]) 6 (7) 4 (3) 6 (6) 0.8 0.2
Hypertension, n (%) 3 (18) 1 (6) 2 (12) 0.6 0.2
Diabetes, n (%) 0 (0) 1 (6) 0 (0) — 0.3
Heart failure, n (%) 0 (0) 1 (6) 0 (0) — 0.3
Myocardial infarction, 
n (%) 0 (0) 0 (0) 0 (0) — —
Type of AF, n (%)
   Paroxysmal 11 (65) 14 (82) — —
   Persistent 6 (35) 2 (12) — —
   Permanent 0 (0) 1 (6) — —
Family history of AF, self-
reported, n (%) 9 (53) 5 (29) — —
Previously ablated, n (%) 8 (47) 3 (18) — —
Physical exercise level, 
self-reported, n (%) 0.6 0.7
   None 1 (6) 0 (0) 1 (6)
   Mild 5 (29) 8 (47) 9 (53)
   Moderate 9 (53) 7 (41) 6 (35)
   Strenuous 1 (6) 2 (12) 1 (6)
Table 1. Baseline characteristics. AF; atrial fibrillation, BMI; body mass index, IQR; interquartile range, NA; 
not available, SD; standard deviation, TTNtv; titin-truncating variant. †Comparisons between AF patients with 
TTNtv and controls. ‡Comparisons between AF patients without TTNtv and controls.
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Comparisons of LA LGE levels in ablated/non-ablated early-onset AF patients with and without TTNtv can 
be found in Fig. 3.
Overall, when evaluating the spatial distribution of LA LGE on MRI scans through eye-balling, we found no 
significant LA LGE in the controls, whereas early-onset AF TTNtv cases without previous ablation had diffusely 
dispersed LA LGE, as exemplified in Supplemental Video 1 and 2 and Supplementary Figure 1.
Discussion
In this study, we investigated the relationship between early-onset AF patients with and without TTNtv and 
dynamic parameters of the left atrium and ventricle and the amount of fibrosis in the atrial wall, using 
state-of-the-art cardiac imaging.
Reduced LVEF in early-onset AF patients. We found that early-onset AF patients with TTNtv had a 
discrete, but statistically significant reduction in LVEF compared with controls. TTNtv have previously been asso-
ciated with cardiomyopathies15 and previous studies have shown that DCM patients with TTNtv have increased 
ventricular interstitial fibrosis and an overall higher rate of ventricular arrhythmias16. In the present study, none 
of the CMR investigated early-onset AF cases had been diagnosed with DCM at the time of study, and echocar-
diographic examinations up to 40 years after diagnosis had been normal in 16 out of 17 patients. Consistent with 
our results, Haggerty et al. found that healthy individuals with TTNtv and without a cardiomyopathy diagnosis 
have a decreased LVEF evaluated by echocardiographic examinations, although more modest compared with 
individuals with TTNtv and cardiomyopathy17. We also found a similar, modest LVEF reduction, in our cohort 
of early-onset AF patients without TTNtv. This may partly be explained by the established link between AF and 
heart failure, or that early-onset AF patients without TTNtv may harbor other structural genetic defects that may 
induce a comparable (albeit more moderate) phenotype as those with TTNtv, compared with older adults with 
a more traditional onset of AF. Of note, the LVEF reference normal value based on SSFP CMR is between 58 
and 76% for healthy 40–49 year old individuals13, and a reduced LVEF, even in the low normal range, has been 
associated with an increased risk of congestive heart failure18. Early-onset AF is in general considered a benign 
AF with 
TTNtv
AF without 
TTNtv Controls P-value† P-value‡
Cardiac index, mL/min/m2 3856 (601) 3903 (618) 3668 (720) 0.436 0.330
Heart rate, bpm 72 (12) 66 (10) 62 (13) 0.018§ 0.264
LA volumes, ml/m2
   LAmini 24 (7) 25 (5) 27 (8) 0.252 0.232
   LAmaxi 52 (12) 55 (10) 60 (11) 0.103 0.264
   LAmdvi 34 (8) 37 (8) 41 (10) 0.059 0.317
   LAbaci 35 (9) 40 (9) 44 (11) 0.025§ 0.278
LA emptying volumes, ml/m2
   LA passive emptying volumei 18 (6) 18 (5) 19 (6) 0.705 0.625
   LA active emptying volumei 11 (4) 15 (5) 16 (4) 0.002§ 0.530
   LA conduit volumei 25 (5) 26 (6) 25 (6) 0.779 0.432
   LA total emptying fraction 54 (9) 56 (6) 55 (6) 0.793 0.571
   LA passive emptying fraction 34 (6) 33 (7) 32 (9) 0.456 0.808
   LA active emptying fraction 32 (9) 38 (7) 37 (5) 0.059 0.817
   LA passive/active ratio 168 (2) 122 (2) 115 (2) 0.032§ 0.739
LA LGE, % 8 (2) 5 (2) 3 (3) <0.001§ 0.064
LV parameters
   LV mass, g/m2 62 (11) 63 (9) 65 (12) 0.408 0.542
   LVEF, % 57 (4) 61 (4) 64 (5) <0.001§ 0.020§
   LVEDV, ml/m2 95 (17) 98 (10) 94 (15) 0.767 0.272
   LVESV, ml/m2 41 (7) 39 (5) 34 (8) 0.013§ 0.033§
   LV stroke volume, ml/m2 53 (1) 59 (1) 59 (1) 0.174 0.980
   LVPFR, ml/s/m2 266 (59) 296 (79) 316 (74) 0.049 0.472
Table 2. cMRI parameters. Values are shown as mean (SD) unless otherwise stated. All volumes are indexed to 
BSA (marked with a subscript i). Individuals with complete volumetric measurements: AF with TTNtv; n = 14, 
AF without TTNtv; n = 15, controls; n = 17. Individuals with complete LA LGE measurements: AF with TTNtv; 
n = 17, AF without TTNtv; n = 17, controls; n = 13. AF, atrial fibrillation; bpm, beats per minute; BSA, body 
surface area; LA, left atrial; LAbac, LA volume before atrial contraction; LAmdv, LA mid-diastolic volume (volume 
after passive emptying but before mid-diastolic expansion); LA LGE, left atrial late gadolinium enhancement; 
LV, left ventricular; LVEF, LV ejection fraction; LVEDV, LV end-diastolic volume; LVESV, LV end-systolic 
volume; LVPFR, LV peak filling rate; SE, standard error; TTNtv, titin-truncating variant. †Comparisons 
between AF patients with TTNtv and controls. ‡Comparisons between AF patients without TTNtv and controls. 
§Statistically significant.
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arrhythmia, and regular clinical assessment, in particular with regards to the functional properties of the heart, is 
not standard. From a clinical perspective, despite that patients with an early presentation of disease may have an 
overall low thromboembolic risk, our study indicates that an early debut of AF may represent an early marker for 
an increased risk of a prematurely failing heart. In this regard, early genetic testing may be warranted to identify 
patients at particularly high risk (TTNtv carrier status), in order to discern carrier status and identify those who 
might benefit from early clinical assessment, and closer follow-up.
Early-onset atrial fibrillation and atrial indices. With regards to the LA measurements, the most 
noticeable difference between the groups was found in the active emptying volume and LA LGE. Compared to 
Figure 2. Left atrial late gadolinium enhancement in all ablated/non-ablated early-onset AF patients. Median 
left atrial late gadolinium enhancement values and interquartile range for controls (n = 13), early-onset AF 
patients without (n = 23) and with (n = 11) ablation, respectively. Y-axis on logarithmic scale. AF, atrial 
fibrillation.
Figure 3. Left atrial late gadolinium enhancement in ablated/non-ablated early-onset AF patients with and 
without TTNtv. Median left atrial late gadolinium enhancement values and interquartile range for controls 
(n = 13), AF patients without TTNtv with (n = 3) and without (n = 14) previous ablation and AF patients with 
TTNtv with (n = 8) and without (n = 9) previous ablation procedures. Y-axis on logarithmic scale. AF, atrial 
fibrillation; TTNtv, titin-truncating variants.
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controls, the active emptying volume was significantly reduced in early-onset AF patients with TTNtv, illustrated 
in the time-volume curves drawn from the volumetric measurements (Fig. 1). This indicates that reductions in 
atrial active emptying could represent a marker for atrial disease whereas atrial passive emptying is correlated 
to LV diastolic dysfunction and found not to be indicative of AF, as previously shown19. Kojima et al. found that 
atrial function was impaired prior to LA enlargement and that this was especially evident for the active function20. 
In fact, we found higher means of LAmax and LAmin in the control group compared with the two early-onset AF 
groups. This may be due to a higher heart rate in the AF patients and possibly due to the fact that many of the 
control subjects were accustomed to moderate or strenuous exercise.
We also identified a significant difference in the amount of LA LGE in early-onset AF cases with TTNtv com-
pared with controls. Early-onset AF patients without TTNtv did not have a significant increase in LA LGE. We 
also found that these differences were not mediated through higher ablation rates in patients with early-onset AF 
(Fig. 2). These findings could indicate that early-onset AF patients in general have an increased level of fibrosis 
in the atrial wall. LA LGE has previously been correlated with active atrial function measured with strain21, indi-
cating that active function and LA LGE are both associated with atrial disease, possibly because they are markers 
of the remodeled LA.
Structural cardiac genes have within recent years been associated with AF, including the sarcomeric protein 
gene myosin light chain 4 (MYL4)6,7,22, SYNPO2L2,23, and lately the TTN gene3 encoding the giant sarcomeric 
protein titin highly expressed in all four heart chambers.
An increase in atrial fibrosis in AF patients compared with non-AF patients24–27 and in lone AF patients com-
pared with non-lone AF patients28 has previously been reported. Kottkamp et al.26 suggested to reclassify some 
lone AF patients as having “fibrotic atrial cardiomyopathy”. Wilson et al. investigated atrial fibrosis in high-risk 
AF pedigrees and found these to have elevated levels, which could indicate that a heritable contribution of atrial 
fibrosis leads to a predisposition to AF29. The relationship between atrial fibrosis and AF is, however, complex, and 
further functional studies are needed to establish whether there is a causal link between levels of fibrosis and AF.
Limitations
The average heart rate was higher in the AF patients (with and without TTNtv) compared with the controls. This 
may have had some impact on LA and LV volumes and function, however not to the extent that we found30.
The LA LGE method has several limitations. Due to a genotype-driven study setup, some AF patients both 
with and without TTNtv had been subjected to ablation therapy, which of course influence the LA LGE measure-
ments. The atrial wall is between 1–4 mm, which often challenges the spatial resolution of the 3D sequence. Thus, 
difficulties in delineation of non-enhanced wall in general includes the risk of also including blood volume and 
epicardial tissue.
Time from early-onset AF diagnosis to CMR scan was on average nearly 20 years. We therefore cannot rule 
out that some of the changes seen are caused by other factors. The lack of significant associations in some com-
parisons could be caused by the modest study size and the results could benefit from replication in larger sample 
sizes.
conclusions
In conclusion, we found evidence of an, albeit subclinical, affected LV systolic function and increased amounts 
of atrial fibrosis in early-onset AF patients. These results indicate that some early-onset AF patients might ben-
efit from early genetic testing and clinical evaluation, in order to establish who should be considered for regular 
clinical assessment.
Data availability
The datasets generated and/or analyzed during the current study are available from the corresponding author on 
reasonable request.
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